腺素受体亚型调节器:洞察分子机制及其治疗应用
Nilay Solanki1, Rohinee Dodiya1,2, Dhruvi Vejpara1
1Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, CHARUSAT Campus Changa 388421, Gujarat, India.
American journal of translational research
|May 19, 2025
概括
腺素受体 (ARs) 影响神经元保护,炎症,心脏健康和癌症. 开发特定的AR配体具有治疗潜力,但需要克服副作用以获得更广泛的临床应用.
科学领域:
- 药理学和分子生物学
- 心血管和神经科学 心血管和神经科学
- 免疫学和瘤学
背景情况:
- 四种腺受体 (AR) 亚型 (A1,A2A,A2B,A3) 调节关键的生理和病理过程.
- ARs与神经保护,炎症,心脏功能和癌症发展有关.
- 特定的AR亚型对包括帕金森病,癌症,喘,糖尿病和自身免疫性疾病在内的疾病具有治疗前景.
研究的目的:
- 审查腺受体亚型的分子机制和组织特异性作用.
- 评估AR向治疗的转化进展.
- 倡导开发具有改善临床结果的选择性AR配体的创新.
主要方法:
- 关于腺受体亚型及其治疗应用的最新科学文献的综述.
- 分析分子机制,生理作用和临床试验数据.
- 检查AR特异性药物开发中的挑战和进展.
主要成果:
- 针对AR特异性激动剂和对抗剂正在研究心力衰竭,缺血,神经退行性疾病和炎症性疾病.
- 目前的AR疗法面临诸多挑战,包括副作用,低受体选择性和物种特异性药物反应.
- 进步包括针对玻璃眼,喘,瘤的选择性药物,以及针对神经退行性疾病和慢性炎症的新策略.
结论:
- 向腺受体为广泛的疾病提供了重要的治疗潜力.
- 克服与选择性和副作用相关的挑战对于实现AR疗法的全部临床益处至关重要.
- 在开发受体特异性配体方面不断的创新对于改变治疗环境至关重要.
相关概念视频
Adrenergic Receptors: ɑ Subtype
1.4K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.4K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
774
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
774
Adrenergic Agonists: Direct-Acting Agents
1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.3K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
518
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
518
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
691
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
691


